Vertex Pharmaceuticals Announces Phase 4 Data Demonstrating JOURNAVX® Enables Opioid-Free Recovery Following Aesthetic and Reconstructive Procedures
Vertex Pharmaceuticals Incorporated today announced new data from a Phase 4 study evaluating JOURNAVX® (suzetrigine), a prescription non-opioid pain signal inhibitor, for the management of moderate-to-severe acute pain in adults undergoing plastic surgical procedures. The findings demonstrated that JOURNAVX, when used as part of a multimodal pain management approach, provided effective pain control and enabled opioid-free recovery for the majority of patients.
In the study, 90.9% of patients remained opioid-free throughout the treatment period, which lasted up to 14 days postoperatively. This result highlights JOURNAVX’s potential as a cornerstone of opioid-sparing therapy following both aesthetic and reconstructive surgeries. By comparison, current literature indicates that opioid-free recovery rates with multimodal therapy excluding JOURNAVX are typically less than 10%, underscoring the significant impact of this therapy. These data are scheduled to be presented at the American Academy of Pain Medicine (AAPM) PainConnect 2026 meeting, taking place March 5-8, 2026, in Salt Lake City, Utah.
The Phase 4 study was open-label, multicenter, and single-arm, evaluating JOURNAVX administered both preoperatively and postoperatively as part of multimodal therapy. Most patients also received acetaminophen and ibuprofen alongside JOURNAVX. The study enrolled 99 patients undergoing a variety of aesthetic and reconstructive procedures, including breast reconstruction and augmentation, liposuction, abdominoplasty with liposuction, and turbinoplasties—surgeries typically associated with moderate-to-severe postoperative pain and standard opioid use for at least 72 hours.
The primary endpoint measured the proportion of patients rating pain control as “excellent,” “very good,” or “good” on the Patient Global Assessment scale at the end of treatment. Results demonstrated that 90.7% of patients (95% CI: 83.1%, 95.7%) rated JOURNAVX as highly effective within the multimodal therapy regimen. Among the nine patients who did require rescue opioids, the average consumption was approximately two tablets over two days, indicating minimal need for supplemental opioid therapy.
JOURNAVX was well tolerated, with no serious adverse events attributed to the drug. Reported adverse events were generally mild or moderate and consistent with those typically observed in the postoperative setting, further supporting its safety profile.
Dr. Samuel Lin, M.D., F.A.C.S., lead author of the study and Director of Aesthetic Surgery at Beth Israel Deaconess Medical Center, emphasized the clinical significance of these findings:
“As a surgeon, effective pain management is a cornerstone of patient recovery. The data from this study highlight the potential of JOURNAVX in enabling opioid-free recovery for patients across a broad range of procedures. By integrating JOURNAVX into a multimodal treatment approach, we are not only providing effective pain relief but also reducing the risks associated with opioid use—an important advancement for both patients and the medical community.”
These findings align with growing efforts in the surgical community to minimize opioid exposure while maintaining high standards of postoperative pain control. JOURNAVX represents a promising addition to multimodal pain management strategies, particularly for procedures where opioid use has historically been routine.
Vertex continues to explore the role of JOURNAVX across multiple surgical settings, aiming to provide clinicians with effective, non-opioid options for managing acute pain. The company plans to further investigate its potential to enhance recovery outcomes, reduce reliance on opioids, and improve patient experiences following surgery.
With the ongoing opioid crisis and heightened awareness of the risks associated with opioid therapy, JOURNAVX offers a clinically meaningful alternative that supports safe, effective, and opioid-sparing postoperative care. By enabling pain control without routine opioid use, the therapy may not only improve recovery for individual patients but also contribute to broader public health goals.
The upcoming AAPM PainConnect 2026 presentation will provide additional details on the study methodology, patient outcomes, and safety profile, offering the medical community valuable insights into the role of non-opioid therapies in modern surgical pain management.
Source Link : https://www.businesswire.com/
